Physician profile
Megan Krease
NPI 1992047716
$2,209.74
in general payments reported to CMS, 2019-2025
21 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $162 · 2021: $389 · 2022: $520 · 2023: $336 · 2024: $415 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $318.92 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $278.34 | 2019-2024 | Dyanavel Xr |
| Seqirus USA INC | $223.76 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Pfizer INC. | $217.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $207.71 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Supernus Pharmaceuticals, INC. | $147.57 | 2021-2024 | Qelbree |
| Corium, LLC | $135.72 | 2021-2023 | Azstarys |
| Sanofi Pasteur INC. | $131.18 | 2020-2025 | |
| Neos Therapeutics, LP | $109.59 | 2019-2023 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $104.58 | 2022-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $102.83 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $48.49 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $36.02 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $34.34 | 2023-2024 | Flumist Quadrivalent |
| Genentech USA, INC. | $22.14 | 2023 | Xofluza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $19.31 | 2024 | Ycanth |
| Noven Therapeutics, LLC | $15.14 | 2025 | Xelstrym |
| Alfasigma USA, INC. | $14.78 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.69 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $13.36 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Krease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.